Welcome to our dedicated page for CORCEPT THERAPEUTICS SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics director Joshua M. Murray received a grant of stock options covering 12,500 shares of Common Stock. The options have an exercise price of $59.69 per share and expire on May 21, 2036.
The award vests ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, conditioned on his continued service on each monthly vesting date. Following the grant, he holds 12,500 stock options directly, with no sales reported in this filing.
Corcept Therapeutics director David L. Mahoney reported a new stock option grant. He received options to acquire 12,500 shares of Corcept common stock at an exercise price of $59.69 per share, expiring on May 21, 2036.
The options were granted as compensation and involve no open-market buying or selling. According to the terms, they become exercisable in equal monthly installments over one year starting on May 21, 2026, contingent on his continued service on each monthly vesting date.
Corcept Therapeutics director Kimberly Park received a stock option grant for 12,500 shares of common stock. The options were granted on May 21, 2026 with an exercise price of $59.69 per share and expire on May 21, 2036.
The award was reported as a grant or other acquisition and is held directly. Following this transaction, Park holds options covering 12,500 shares. According to the footnote, the options become exercisable in equal monthly installments over a one-year period starting on May 21, 2026, contingent on her continued service on each vesting date.
An affiliate of CORT submitted a Form 144 proposing the sale of 5,000 shares of Common Stock. The filing lists $291,100.00 as an aggregate amount and identifies Fidelity Brokerage Services LLC as the broker. The filing shows a date of 05/20/2026 and a reference number 107351594.
Corcept Therapeutics’ Chief Business Officer Gary Charles Robb reported several bona fide gifts of Corcept Therapeutics common stock and updated his indirect holdings. On May 13, 2026, he gifted 5,300 shares from his direct holdings and two gifts of 1,000 shares each from custodial accounts for a child, totaling 7,300 shares. After these gifts, he directly holds 24,487 shares, while a custodial account for a child holds 12,571 shares and a revocable trust holds 49,716 shares. Footnotes also note unvested restricted stock awards of 997, 251, 224 and 499 shares, each scheduled to vest in full on the one-year anniversary of their respective grant dates if specified conditions are met.
Corcept Therapeutics’ Chief Development Officer William Guyer exercised stock options and sold shares on May 5, 2026. He exercised options to acquire 20,000 shares of common stock at $21.65 per share, then sold 20,000 shares in an open-market transaction at a weighted average price of $51.83 per share, with actual prices ranging from $51.60 to $52.05. Following these transactions, he directly holds 2,231 common shares, which include 224 and 498 shares underlying unvested restricted stock awards that each vest in full one year after their respective grant dates if conditions are met. He also holds 170,000 fully exercisable stock options with a $21.65 exercise price expiring on September 1, 2031. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024.
Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff reported an open-market sale of 40,000 shares of Common Stock on May 1, 2026 at a weighted average price of $50.0965 per share. The transaction was executed indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which he has voting power pursuant to voting agreements.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024. Following this transaction, the trust holds 2,878,326 shares of Corcept Therapeutics Common Stock, for which Belanoff disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics Inc. files a Form 144 reporting an intended sale of 20,000 shares of Common Stock through Stifel Nicolaus & Company Inc. on 05/05/2026 via a stock option exercise for cash. The filing also lists three prior dispositions by William Guyer on 03/04/2026, 03/20/2026, and 04/08/2026 totaling 40,000 shares reported with dollar amounts alongside each sale.
Corcept Therapeutics reported a proposed sale of 40,000 shares of Common Stock under Rule 144 via broker Stifel Nicolaus & Company Inc.. The filing also records a prior sale of 26,198 shares on 03/25/2026 for $1,311,825.
Corcept Therapeutics generated Q1 2026 net product revenue of $164.9 million, up modestly year over year, but swung to a net loss of $31.8 million versus prior profit. The loss reflected sharply higher selling, general and administrative costs of $145.4 million and research and development spending of $66.3 million.
The company ended March 31, 2026 with cash, cash equivalents and marketable securities totaling $515.4 million, providing substantial funding for ongoing programs. In March 2026, the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer, and U.S. sales began in April, adding a new oncology revenue stream alongside Korlym and its authorized generic.